Morgan Stanley initiated coverage of Omada Health (OMDA) with an Overweight rating and $25 price target Omada Health is becoming an integral solution to drive adherence in treating obesity, diabetes and hypertension, large markets impacting more than 120 million people, the analyst tells investors in a research note. Revenue upside and AI automation should drive margins higher, a key catalyst for multiple expansion, the firm says.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health initiated with a Buy at Goldman Sachs
- JPMorgan Issues Buy Rating for Omada Health, Inc. Citing Growth Potential in Underpenetrated $135 Billion Market and Strategic Partnerships
- Omada Health: A Compelling Investment Opportunity in Digital Health with Strong Growth Potential
- Omada Health: Strong Growth Prospects and Path to Profitability with Undervalued Potential
- Opening Day: Jefferson Capital makes public debut in slow week